BioNTech (BNTX) to Release Quarterly Earnings on Wednesday

BioNTech (NASDAQ:BNTX) will likely be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect BioNTech to post earnings of $0.38 per share for the quarter. BioNTech has set its FY 2025 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Price Performance

BioNTech stock opened at $99.47 on Monday. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a market capitalization of $23.85 billion, a price-to-earnings ratio of -47.37 and a beta of 0.30. The company has a fifty day simple moving average of $115.49 and a 200-day simple moving average of $113.37. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BNTX. Berenberg Bank initiated coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Morgan Stanley dropped their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Wells Fargo & Company initiated coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective for the company. Truist Financial initiated coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Finally, BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.